The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

Vipul R. Patel, MD, FACS, is a board-certified urologic surgeon, medical director of the Global Robotics Institute at AdventHealth, and medical director of urologic oncology at AdventHealth Cancer ...

Prostate cancer is the most common solid tumor in male patients. Roughly 70,000 U.S. adults each year are diagnosed with intermediate-risk disease confined to the prostate, for which radiation therapy ...

Targeted therapies are medicines to treat cancer. They work differently than standard chemotherapy. Instead of killing all fast-growing cells or keeping them from dividing, targeted therapies work ...

Short-term androgen deprivation combined with high-dose radiation therapy aids oncologic control in localized prostate cancer. In patients with intermediate- or high-risk localized prostate cancer, ...

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer.

Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that returned after radiotherapy. Matched analyses estimated 10-year ...